By Elie Dolgin, Milwaukee Journal Sentinel
Aug. 4–Nearly one-quarter of the human stem cell lines approved for federal funding by the Bush administration may have serious ethical problems, according to a report by University of Wisconsin-Madison bioethicist Robert Streiffer.
Streiffer reviewed the informed consent forms of the 21 embryonic stem cell lines eligible for taxpayer dollars and concluded that five of the lines were marred by major ethical concerns.
“There was a range of acceptability,” Streiffer said. “Some (consent forms) were well done, but others did not provide enough information and detail to count as informed consent.”
On Aug. 9, 2001, President Bush, citing moral concerns over stem cell research, announced that federal funding would be restricted to only those colonies, or “lines,” of embryonic stem cells derived before that date. The consent forms were completed by the donors between 1997 and 2001.
For three of the Bush-approved lines derived by Athens, Ga.-based BresaGen, the informed consent forms were not for research but for patients to begin fertility treatment, with only a vague mention that some embryos might be used for research.
For two other cell lines, created by Swedish biotechnology company Cellartis, women donated embryos for a specific research experiment, but the consent forms stated that the cells would subsequently be destroyed.
“It’s not that they are unacceptable consent forms; they’re just acceptable for only certain kinds of research,” said Streiffer, who published his findings in the journal Hastings Center Report. “Without looking at the original consent forms, I don’t think you can say you can use them for any type of research.”
All 21 cell lines are routinely used by researchers around the country without additional stipulations or limitations relating to the original informed consent given by the donors.
Last year, UW-Madison created a Stem Cell Research Oversight Committee that will soon consider the ethical appropriateness of all current and future stem cell research projects on the campus.
“All human stem cell research will need to be reviewed and approved by the committee, and that will include how cells were obtained and if the consent was adequate,” said Norman Fost, a committee member and UW-Madison pediatrics professor.
The committee has not discussed Streiffer’s specific findings, though, said committee chair and UW-Madison physiology professor Richard Moss.
“An important step for us is to take into account these findings,” Moss said, “but we haven’t done that as a group, and we haven’t reached a decision on these cell lines.”
Other large research institutions, however, including Stanford University in Palo Alto, Calif., and Johns Hopkins University in Baltimore, have responded directly to Streiffer’s study and are assessing the appropriateness of these particular cell lines, the Center for American Progress, a left-leaning think tank in Washington, D.C., reported last month.
UW-Madison does not maintain a record of what cell lines are used by its researchers, and until the committee is active, they will not know if any of the five cell lines are currently used, both Fost and Moss said.
Stephen Duncan, director of the program in regenerative medicine at the Medical College of Wisconsin in Wauwatosa, said no one in his program uses any of the five lines in question.
Madison-based WiCell, an affiliate of the Wisconsin Alumni Research Foundation, maintains and distributes 15 of the Bush-approved cell lines — including the three BresaGen lines called into question — through its National Stem Cell Bank.
WiCell has been distributing the three BresaGen lines only since January, however. And since then, they have been dispatched only twice among over 700 total cell line requests, said Janet Kelly, WiCell’s communications director.
WiCell is under contract from the National Institutes of Health to host the cells and will continue to distribute all the available cell lines unless told otherwise by the NIH, Kelly noted.
A statement released by the NIH said that it “required the deriver or provider of each candidate cell line to provide written assurance that all the criteria set forth by the President had been fulfilled, including the specified components of the informed consent process.”
Since 2001, scientists have developed hundreds of new embryonic stem cells lines using ethically and scientifically improved methods, but none of these lines has been eligible for federal funds.
Based on his findings, Streiffer argues that cell lines should be judged on how, rather than when, they were obtained.
“It doesn’t make sense to fund or not fund research just because of when a stem cell line was derived,” he said. “It’s preferable to use cell lines that have even better consent than ones used on the (Bush-approved) registry.”
The study “points to the fact that this policy is not tenable anymore,” said Jonathan Moreno, a medical ethicist at the University of Pennsylvania and a senior fellow with the Center for American Progress.
—–
To see more of the Milwaukee Journal Sentinel, or to subscribe to the newspaper, go to http://www.jsonline.com.
Copyright (c) 2008, Milwaukee Journal Sentinel
Distributed by McClatchy-Tribune Information Services.
For reprints, email [email protected], call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.
Comments